BioOutsource ramps up investment in R&D to prepare for biosimilars boom
3 November 2014 | By BioOutsource Ltd
BioOutsource Ltd. announced a major initiative in new research and development programs to support the next generation of biosimilars...
List view / Grid view
News
Almirall completes deal with Astrazeneca in respiratory disease
3 November 2014 | By Almirall
Almirall announced that, effective November 1st, it has completed the transaction to transfer to AstraZeneca the rights of Almirall’s respiratory franchise after all closing conditions have been satisfied...
Bristol-Myers Squibb’s ZymoGenetics R&D facility earns LEED Silver Certification from U.S. Green Building Council
31 October 2014 | By Bristol-Myers Squibb
ZymoGenetics is among an elite group of laboratories around the world that have earned the U.S. Green Building Council’s LEED® (Leadership in Energy and Environmental Design) Silver certification for Existing Buildings: Operations and Maintenance...
Actinogen Ltd acquires Edinburgh BioQuarter spin-out to develop treatment for Alzheimer’s dementia
31 October 2014 | By Actinogen Ltd
Actinogen Ltd, an Australian biotechnology company, has acquired Edinburgh BioQuarter spin-out, Corticrine Ltd in a deal facilitated and introduced by Professor Alan Boyd of Boyds...
Bristol-Myers Squibb and Lonza expand biologics manufacturing agreement
Bristol-Myers Squibb Company and Lonza today announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms were not disclosed.
New Genital Herpes vaccine entrants require improved efficacy to compete, says GlobalData analyst
31 October 2014 | By GlobalData
While the collaboration between Sanofi Pasteur (Sanofi) and Immune Design to develop a genital herpes vaccine presents a strong scientific foundation and difficult-to-match financial clout, the partnership needs to create a product with better clinical performance to compete with more advanced pipeline vaccine candidates, says an analyst with research and…
Phase 2 data for Opdivo (nivolumab) to be presented
30 October 2014 | By Bristol-Myers Squibb
Phase 2 objective response rate and survival data for Opdivo (nivolumab) in heavily pre-treated advanced squamous cell non-small cell lung cancer to be presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology...
Auditing is theme for next BGMA Quality Forum
Auditing will be a key theme of the British Generic Manufacturers Association’s (BGMA) next BGMA Quality Forum meeting on Wednesday, November 12th which is run in partnership with the MHRA.
Lilly shares technology insights to increase supply of medicines for multidrug-resistant tuberculosis
30 October 2014 | By Eli Lilly and Company
Eli Lilly and Company published details of its long-standing technology transfer program to increase the global supply of medicines for multidrug-resistant tuberculosis (MDR-TB)...
Celebrating the best of pharma and recognizing companies that turn inspiration into innovation
30 October 2014 | By PresseBox
It has become a tradition to recognize pharma innovation at CPhI Worldwide, as CPhI Pharma awards winners driving Pharma's biggest innovations...
Merck Forms a Scientific Partnership with Kenya Medical Research Institute (KEMRI) as part of its Capacity Advancement Program in Africa
29 October 2014 | By Merck
Merck announced today the signature of a memorandum of understanding with Kenya Medical Research Institution (KEMRI) for a scientific partnership aimed at contributing to the country’s social and economic development. The partnership will cover research and development projects, programs and activities focused on malaria and schistosomiasis, as well as related…
Global Non-Hodgkin Lymphoma therapeutics market value to hit $9.2 billion by 2020
29 October 2014 | By GBI Research
The global Non-Hodgkin Lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 7.4%, says business intelligence provider GBI Research...
Lilly to participate in Credit Suisse 2014 Healthcare Conference
29 October 2014 | By Eli Lilly and Company
Eli Lilly and Company (LLY) will participate in the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix, AZ, on Wednesday, November 12, 2014. Jeffrey Simmons, Senior Vice President and President, Elanco Animal Health, will make a formal presentation at 1:30 p.m. EST...
Christopher A. Viehbacher removed as Sanofi’s Chief Executive Officer
29 October 2014 | By Sanofi
Sanofi's Board of Directors have decided unanimously to remove Christopher A. Viehbacher as Chief Executive Officer of Sanofi. As a consequence Christopher A. Viehbacher resigned as a director of Sanofi...
Lilly responds to decision in case of Terrence Allen, et al. v. Takeda
28 October 2014 | By Eli Lilly &Company
Eli Lilly and Company LLY, -2.58% issued the following statement in response to a judge's ruling that the punitive damages awarded in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 be reduced...
